PLUS THERAPEUTICS Inc.

News & Events

Press Releases

In The Media

1. Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

   GlobeNewswire APR 23, 2025 8:00 AM EDT
   HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the ...
   READ ARTICLE

2. Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

   GlobeNewswire APR 15, 2025 7:30 AM EDT
   HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the ...
   READ ARTICLE

3. Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

   GlobeNewswire MAR 27, 2025 4:05 PM EDT
   HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the ...
   READ ARTICLE

4. Plus Therapeutics Introduces REYOBIQ(TM), FDA-Accepted Proprietary Name for Lead Drug Candidate

   GlobeNewswire MAR 20, 2025 7:30 AM EDT
   REYOBIQ™ (rhenium Re 186 obisbemeda) continues to be under clinical investigation for ...
   READ ARTICLE

5. Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

   GlobeNewswire MAR 19, 2025 7:30 AM EDT
   HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the ...
   READ ARTICLE

6. D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

   ACCESS Newswire MAR 11, 2025 11:00 AM EDT
   HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics , Inc. (Nasd...
   READ ARTICLE

7. Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

   GlobeNewswire MAR 10, 2025 7:30 AM EDT
   HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV ) (the...
   READ ARTICLE

8. Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

   GlobeNewswire MAR 7, 2025 7:30 AM EST
   Rhenium ( 186 Re) Obisbemeda demonstrates safety, response, and potential efficacy fo...
   READ ARTICLE

9. Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

   GlobeNewswire MAR 6, 2025 7:30 AM EST
   HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV ) (the...
   READ ARTICLE

10. Plus Therapeutics Announces New Employment Inducement Grants

    GlobeNewswire MAR 5, 2025 4:01 PM EST
    HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (...
    READ ARTICLE